Ruxolitinib: In the Treatment of Myelofibrosis

Author： Yang Lily P.H.   Keating Gillian M.  

Publisher： Adis International

ISSN： 0012-6667

Source： Drugs, Vol.72, Iss.16, 2012-11, pp. : 2117-2127

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis

By Vaddi Kris   Sarlis Nicholas J   Gupta Vikas  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 16, 2012-11 ,pp. : 2397-2407

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety of ruxolitinib in intermediate‐1 IPSS risk myelofibrosis patients: Results from an independent study

By  

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 285-290

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib

By  

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 357-359

John Wiley & Sons Inc

Access to resources Recommend Favorite

A potential role of ruxolitinib in leukemia

By Naqvi Kiran   Verstovsek Srdan   Kantarjian Hagop   Ravandi Farhad  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 8, 2011-08 ,pp. : 1159-1166

Informa Healthcare

Access to resources Recommend Favorite

Emerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofibrosis

By Gowin Krisstina   Mesa Ruben  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 12, 2013-12 ,pp. : 1603-1611

Informa Healthcare

Access to resources Recommend Favorite